Résztvevőt keres itt: Egyesült ÁllamokFázis nélkül
Acute Pulmonary Embolism Treatment With the AlphaVac Multipurpose Mechanical Aspiration System and the AlphaReturn Blood Management System: Evaluation of Safety and Effectiveness
A legfontosabb adatok
- Ki végzi
- Angiodynamics, Inc.
- Hol
- Buffalo, Kettering, Plano, Saint Cloud, San Antonio és The Bronx (Egyesült Államok)Mind a 6 helyszín megnézése
- Azonosító
- Állapot
- Toboroz
- Résztvevők
- 39 fő, tervezett
- Kezdés
- 2026. márc. 30.
- Várható befejezés
- 2026. dec.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- AlphaReturn Blood Management System
- A regiszteradat frissítve
- 2026. május 11.
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 32 feltétel megnézéseKevesebb
Ki vehet részt
- A potential subject will be included in the study if he/she meets all the following inclusion criteria:
- Provision of signed and dated informed consent form
- Subject is 18 years of age and older
- Subject presents clinical signs and symptoms consistent with acute intermediate-risk pulmonary embolism for less than or equal to 14 days
- Subject has a diagnosis of pulmonary embolism detected from computed tomography angiography (CTA)
- Subject has a RV/LV ratio of 0.9 or higher
- Subject has a systolic blood pressure (SBP) of 90mmHg or higher
- Subject has a heart rate of 130 beats per minute (BPM) or less prior to the procedure
- Subject is deemed medically eligible for interventional procedure(s) per institutional guidelines and/or clinical judgment
Ki nem vehet részt
- Subjects who have used thrombolytics in the 30 days prior to the baseline CTA
- Subjects who have had a cardiovascular or pulmonary surgery within the past 7 days of index procedure
- Subjects with known anaphylactic reaction to radiographic contrast agents that cannot be pretreated
- Subjects who have pulmonary hypertension with peak pulmonary artery pressure (PAP) > 70 mmHg
- Subjects with the presence of cancer requiring active chemotherapy
- Subjects with known bleeding diathesis or coagulation disorder
- Subjects with platelets count < 100,000/μL
- Subjects with serum creatinine > 1.8 mg/dL
- Subjects with International Normalized Ratio (INR) > 3
- Subjects with a history of severe or chronic pulmonary hypertension, uncompensated heart failure, chest irradiation, underlying lung disease that is oxygen dependent, heparin-induced thrombocytopenia (HIT) and/or chronic left heart disease with left ventricular ejection fraction ≤ 30%
- A potential subject will be excluded from the study if he/she meets any of the following exclusion criteria:
- Subjects who are or may be pregnant as determined by a positive pregnancy test or who are breastfeeding
- Subjects who have any contraindication to systemic or therapeutic doses of heparin or anticoagulants
- Subjects who have FiO2 requirement > 44% or > 6 LPM to keep oxygen saturations > 90%
- Subjects with hematocrit < 28% within 6 hours of index procedure
- Subjects who have undergone a major trauma within the past 14 days of the index procedure and have Injury Severity Score (ISS) > 15
- Subject requires vasopressor after fluids to keep pressure ≥ 90mmHg
- Subjects with left bundle branch block
- Subjects who have intracardiac lead in the right ventricle or atrium
- Evidence such as imaging or other that suggest the subject is not appropriate for this procedure
- Subjects that have life expectancy < 90 days, in the opinion of the investigator at the time of enrollment
- Subjects dependent on extracorporeal life support such as extracorporeal membrane oxygenation (ECMO)
- Participation in another investigational study
Helyszínek itt: Egyesült Államok
- University at BuffaloBuffalo, Egyesült ÁllamokContact: Monica NowakRésztvevőt keres
- Kettering HealthKettering, Egyesült ÁllamokContact: Chris SegerRésztvevőt keres
- Baylor Heart Hospital - PlanoPlano, Egyesült ÁllamokContact: Christopher QuiochoRésztvevőt keres
- Centracare Heart and Vascular CenterSaint Cloud, Egyesült ÁllamokContact: Kelly KobylinskiRésztvevőt keres
- Methodist HealthcareSan Antonio, Egyesült ÁllamokContact: Susana MondacaRésztvevőt keres
- Jacobi Medical CenterThe Bronx, Egyesült ÁllamokContact: Cidney SchultzRésztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
The investigation is intended to evaluate the safety and effectiveness of the AlphaReturn Blood Management System when used in conjunction with the cleared AlphaVac MMA F1885 System for the treatment of acute pulmonary embolism.
A vizsgálat csoportja
- AlphaVac MMA F1885 System and AlphaReturn Blood Management SystemA vizsgált kezelés
Following mechanical thrombectomy using the AlphaVac MMA System, the treating physician will filter the aspirated blood using the AlphaReturn Blood Management System and reinfuse the filtered autologous blood back into the patient.
Kezelés: AlphaReturn Blood Management System
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Acute Pulmonary Embolism Treatment With the AlphaVac Multipurpose Mechanical Aspiration System and the AlphaReturn Blood Management System: Evaluation of Safety and Effectiveness (APEX-Return)
- A regiszteradat frissítve
- 2026. május 11.